Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Tramiprosate

Generic Name: Tramiprosate

Drug Type: Small Molecule

Chemical Formula: C_₃H_₉NO_₃S

CAS Number: 3687-18-1

Unique Ingredient Identifier: 5K8EAX0G53

Overview

No overview information available.

Background

No background information available.

Indication

Investigated for use/treatment in strokes and alzheimer's disease.

Associated Conditions

No associated conditions information available.

Clinical Trials

The Effects of Cannabidiol and Homotaurine in Patients With Mild Cognitive Impairment

Phase 4

Posted: 2021/08/26

Sponsor:Aristotle University...

ID:NCT05022186

Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease

Phase 3

Posted: 2006/04/17

Sponsor:

Bellus Health Inc. -...

ID:NCT00314912

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

FDA Aligns with Enabled Therapeutics on CPT-021: Novel Targeted Therapy for Alzheimer's Disease

2 months ago

Enabled Therapeutics successfully completed FDA pre-IND meeting for CPT-021, a first-in-class neuroinflammation-targeted oral therapy for Alzheimer's disease, with regulatory alignment on development plans.

Alzheon to Present Phase 3 Data for ALZ-801, Aiming to Slow Alzheimer's Progression

4 months ago

Alzheon is set to present Phase 3 trial data for ALZ-801 in April 2025, a drug designed to prevent the formation of toxic beta-amyloid plaques in early Alzheimer's patients with the ApoE4 gene.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy